A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes

Diabetes Care

Volumn 22, Issue 3, 1999, Pages 463-467

  Wolffenbuttel, Bruce H R ^a   Landgraf, Rüdiger ^b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; REPAGLINIDE; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; OUTPATIENT CARE; RANDOMIZED CONTROLLED TRIAL;

EID: 0033009186     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.22.3.463     Document Type: Article

References (17)

1. DeFronzo RA: The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37:667-687, 1988
2. Yki-Jarvinen H: Pathogenesis of non-insulin-dependent diabetes mellitus. Lancet 343:91-95, 1994
3. Stenman S, Melander A, Groop PH, Groop LC: What is the benefit of increasing the sulfonylurea dose? Ann Intern Med 118: 169-172, 1993
4. Groop LC, Luzi L, DeFronzo RA, Melander A: Hyperglycaemia and absorption of sulphonylurea drugs. Lancet ii:129-130, 1989
5. Lebovitz HE, Melander A: Sulfonylureas: basic aspects and clinical uses. In International Textbook of Diabetes Mellitus. Alberti KGMM, DeFronzo RA, Keen H, Zimmet P, Eds. New York, Wiley, 1992, p. 745-772
6. Asplund K, Wiholm B-E, Lithner F: Glibenclamide-associated hypoglycaemia: a report on 57 cases. Diabetologia 24:412-417, 1983
7. Williams G: Management of non-insulin-dependent diabetes mellitus. Lancet 343: 95-100, 1994
8. Wolffenbuttel BHR, Nijst L, Sels JP, Menheere PPCA, Muller PG, Nieuwenhuijzen Kruseman AC: Effects of a new oral hypoglycemic agent, repaglinide, on metabolic control in sulfonylurea-treated patients with NIDDM. Eur J Clin Pharmacol 45:113-116, 1993
9. World Health Organization: Diabetes Mellitus: Report of a WHO Study Group. Geneva, World Health Org., 1985 (Tech. Rep. Ser., no. 727)
10. World Medical Association: World Medical Association Declaration of Helsinki: Recommendations Guiding Physicians in Biomedical Research Involving Human Subjects. Amended by the 41st World Medical Assembly, Hong Kong, September 1989. Nord Med 107:24-25, 1992
11. Rains SGH, Wilson GA, Richmond W, Elkeles RS: The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes. Diabet Med 5:653-658, 1988
12. Marbury TC, Hatorp V: Pharmacokinetics of repaglinide after single and multiple doses in patients with renal impairment compared with normal healthy volunteers (Abstract). Diabetes 47 (Suppl. 1):357A, 1998
13. Damsbo P, Andersen PH, Lund S, Porksen N: Improved glycaemic control with repaglinide in NIDDM with 3 times daily meal related dosing (Abstract). Diabetes 46 (Suppl. 1):34A, 1997
14. Tronier B, Marbury TC, Damsbo P Windfeld K: A new oral hypoglycaemic agent, repaglinide, minimises risk of hypoglycaemia in well controlled NIDDM patients (Abstract). Diabetologia 38 (Suppl. 1):195A, 1995
15. Hadden DR, Blair ALT, Wilson EA: Natural history of diabetes presenting age 40-69 years: a prospective study of the influence of intensive dietary therapy. Q J Med 59:579-598, 1986
16. Rudenski AS, Hadden DR, Atkinson AB, Kennedy L, Matthews DR, Merrett JD, Pockaj B, Turner RC: Natural history of pancreatic islet B-cell function in type 2 diabetes mellitus studied over six years by homeostasis model assessment. Diabet Med 5:36-41, 1987
17. O'Connor PJ, Fragneto R, Coulehan J, Crabtree BF: Metabolic control in non-insulin-dependent diabetes mellitus: factors associated with patient outcomes. Diabetes Care 10:697-701, 1987